Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Syndax Announces Participation at Two Upcoming Investor Conferences | ||
| By: PR Newswire Association LLC. - 01 Feb 2024 | Back to overview list |
|
|
WALTHAM, Mass., Feb. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:
A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. Syndax Contacts Sharon Klahre SNDX-G
SOURCE Syndax Pharmaceuticals, Inc. 
|
||
|
||
 | Back to overview list | |
View original content: